期刊文献+

MiR-122在肝细胞癌中的表达及其与肿瘤表型标志物的相关性研究 被引量:6

Study of correlation between the expression of mir-122 and phenotype marker
原文传递
导出
摘要 目的检测肝细胞癌(HCC)组织中miR-122和上皮性钙粘蛋白(E-cadherin)、转化生长因子-β1(TGF-β1)的表达,并分析miR-122与E-cadherin、TGF-β1之间的相关性。方法应用实时荧光定量PCR技术检测45例HCC及其配对癌旁组织中miR-122的表达情况;免疫组织化学法检测上述HCC及其配对癌旁组织中E-cadherin、TGF-β1的表达,分析miR-122的表达量与E-cadherin、TGF-β1之间的相关性。结果 miR-122在肝癌组织低表达,肝癌组织中miR-122表达量低于其癌旁组织者有41例,表达量相仿或高于其癌旁组织者4例,差异具有统计学意义(P<0.05)。E-cadherin在HCC组织中的表达显著低于癌旁组织(P<0.05),HCC组织中TGF-β1表达显著高于癌旁组织(P<0.05)。HCC组织中miR-122表达与E-cadherin呈正相关(r=0.827),与TGF-β1表达呈负相关(r=-0.356)。结论 miR-122在HCC组织中低表达,其表达量与肝癌分化程度正相关。 Objective To detect the expression of microRNA-122 (miR-122), E-cadherin(E-cad) protein, transforming growth factor-β1(TGF-β1) protein and analyze the correlation between the expression of miR-122 and E-cad, TGF--β1 in the samples of patients with HCC. Methods The quantitative reverse transcription-PCR was used to detect the expression of miR-122 in 45 patients with HCC and the immunohistochemical method was used to detect the expression of E-cadherin and TGF-β1 protein in the tissues of HCC patients.The correlation between the miR-122 and the E-cadherin,TGF-β1 was analyzed. Results The expression of miR-122 was low in HCC and the expression of tumor tissues was lowed than side-tumor tissues in 41 patients with HCC and there were significant differences between them(P〈0.05).The expression of E-cadherin was significantly lower in tumor tissues and the side-tumor tissues(P〈0.05). The expression of TGF-β1 was significantly higher in tumor tissues and the side-tumor tissues(P〈0.05). It showed positive correlation between the miR-122 expression and the E-cadherin expression and it showed negative correlation between the miR-122 expression and the TGF-β1 expression. Conclusion The expression of miR-122 in the patients with HCC was low and correlated positively with the tumor differentiation of HCC.
出处 《中华临床医师杂志(电子版)》 CAS 2013年第24期131-133,共3页 Chinese Journal of Clinicians(Electronic Edition)
基金 云南省应用基础研究计划项目(2001FB159)
关键词 肝细胞 MIR-122 E-CADHERIN 转化生长因子Β1 Carcinoma, hepatocellular miR-122 E-cadherin Transforming growth factor betal
  • 相关文献

参考文献14

  • 1Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005.74-108.
  • 2Thorgeirsson SS,Lee JS,Grisham JW. Functional genomics of hepatocellular carcinoma[J].{H}HEPATOLOGY,2006.S145-S150.
  • 3Varnholt H,Drebber U,Schulze F. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma[J].{H}HEPATOLOGY,2008.1223-1232.
  • 4Giannel i G,Bergamini C,Fransvea E. Laminin-5 With Transforming Growth Factor-β1 Induces Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma[J].{H}GASTROENTEROLOGY,2006.287.
  • 5Thiery JP. Epithelial-mesenchymal transitions in development and pathologies[J].Curr Opin cellBiol,2003.740-746.
  • 6Bracken CP,Gregory PA,Khew-Goodall Y. The role of microRNAs in metastasis and Epithelial-mesenchymal Transition[J].{H}Cellular and Molecular Life Sciences,2009.1682-1699.
  • 7Andorfer CA,Necefa BM,Thompson EA. MicroRNA signature clinical biomarkers of the diagnosis and treatment of breast cancer[J].{H}Trends in Molecular Medicine,2011.313-319.
  • 8Coulouarn C,FactorVM,Andersen JB. Loss ofmiR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties[J].{H}ONCOGENE,2009.3526-3536.
  • 9Bai S,Nasser MW,Wang B. MicroRNA-122 inhibits tumorigenic properties ofhepatocellular carcinoma cells and sensitizes these cells to sorafenib[J].{H}Journal of Biological Chemistry,2009.32015-32027.
  • 10Tavazoie SF,Alarcon C,Oskarsson T. Endogenous human microRNAs that suppress breast cancer metastasis[J].{H}NATURE,2008.147-152.

二级参考文献2

共引文献6

同被引文献122

  • 1马明.原发性肝癌手术治疗效果及预后因素分析[J].医学信息(医学与计算机应用),2014,0(33):317-318. 被引量:1
  • 2魏明,涂玲,梁颖红,刘佳,张俊华,龚艳杰.肺癌患者外周血CEA mRNA、CK19 mRNA和CK20 mRNA的表达[J].中国老年学杂志,2014,34(2):490-491. 被引量:1
  • 3曾爱华,何蕴韶,李虎,王穗海.实时荧光定量PCR检测乳腺癌5种多药耐药基因的表达强度[J].陕西医学杂志,2005,34(2):135-137. 被引量:4
  • 4Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer[J]. Cancer Cell, 2008, 13(2):153-166.
  • 5Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822):1245-1255.
  • 6Roberts LR. Sorafenib in liver cancer--just the beginning[J]. N Engl J Med, 2008, 359(4):420-422.
  • 7Hao K, Luk JM, Lee NP, et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters[J]. BMC Cancer, 2009, 9:389. doi: 10.1186/1471-2407-9-389.
  • 8Wei L, Lian B, Zhang Y, et al. Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma[J]. BMC Genomics, 2014, 15(Suppl 1):S13.
  • 9Gu Z, Zhang C, Wang J. Gene regulation is governed by a core network in hepatocellular carcinoma[J]. BMC Syst Biol, 2012, 6:32. doi: 10.1186/1752-0509-6-32.
  • 10Ambros V. The functions of animal microRNAs[J]. Nature, 2004, 431(7006):350-355.

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部